Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers

dc.authorid0000-0002-3285-417X
dc.authorid0000-0003-4304-9245
dc.authorid0000-0003-1864-0316
dc.authorid0000-0001-9962-8882
dc.authorid0000-0003-2131-2866
dc.authorscopusid56545735000
dc.authorscopusid24471549000
dc.authorscopusid6602557128
dc.authorscopusid57189243089
dc.authorscopusid56370690600
dc.authorscopusid14022986200
dc.authorscopusid55672209100
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidBaşcı, Semih/AAB-4823-2021
dc.authorwosidYigenoglu, Tugce/ABF-6595-2021
dc.authorwosidBasturk, Abdulkadir/B-1962-2018
dc.contributor.authorBaşcı, Semih
dc.contributor.authorAta, Naim
dc.contributor.authorAltuntaş, Fevzi
dc.contributor.authorYigenoğlu, Tuğçe Nur
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorKorkmaz, Serdal
dc.contributor.authorBirinci, Şuayip
dc.contributor.authorTurgut, Burhan
dc.date.accessioned2022-05-11T14:40:04Z
dc.date.available2022-05-11T14:40:04Z
dc.date.issued2022
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractPrevious studies reported that COVID-19 patients with cancer had higher rates of severe events such as intensive care unit (ICU) admission, mechanical ventilation (MV) assistance, and death during the COVID-19 course compared to the general population. However, no randomized study compared the clinical course of COVID-19 in patients with hematologic cancers to patients with solid cancers. Thus, in this study, we intend to reveal the outcome of COVID-19 in hematologic cancer patients and compare their outcomes with COVID-19 patients with solid cancers. The data of 926 laboratory-confirmed COVID-19 patients, including 463 hematologic cancer patients and an age-gender paired cohort of 463 solid cancer patients, were investigated retrospectively. The frequencies of severe and critical disease, hospital and ICU admission, MV assistance were significantly higher in hematologic cancer patients compared with the solid cancer patients (p = 0.001, p = 0.045, p = 0.001, and p = 0.001, respectively). The hospital stay was longer in patients with hematologic cancers (p = 0.001); however, the median ICU stay was 6 days in both groups. The case fatality rate (CFR) was 14.9% in patients with hematologic cancers, and it was 4.8% in patients with solid cancers, and there was a statistically significant difference regarding CFR between groups (p = 0.001). Our study revealed that COVID-19 patients with hematologic cancers have a more aggressive course of COVID-19 and have higher CFR compared to COVID-19 patients with solid cancers and support the increased susceptibility of patients with hematologic cancers during the outbreak.
dc.identifier.doi10.1007/s11739-021-02784-y
dc.identifier.endpage139
dc.identifier.issn1828-0447
dc.identifier.issn1970-9366
dc.identifier.issue1en_US
dc.identifier.pmid34110562
dc.identifier.scopus2-s2.0-85107801967
dc.identifier.scopusqualityQ1
dc.identifier.startpage135
dc.identifier.urihttps://doi.org/10.1007/s11739-021-02784-y
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8850
dc.identifier.volume17
dc.identifier.wosWOS:000659852100004
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorTurgut, Burhan
dc.language.isoen
dc.publisherSpringer-Verlag Italia Srl
dc.relation.ispartofInternal and Emergency Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectHematologic cancer
dc.subjectSolid tumor
dc.titlePatients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
8850.pdf
Boyut:
406.37 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text